Publication for BL12: A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients with Advanced Urothelial Cancer Progressing on or after a Platinum Containing Regimen


https://jamanetwork.com/journals/jamaoncology/article-abstract/2770261?resultClick=1

The purpose of this study was to compare the effects on urothelial cancer of nab-paclitaxel compared to paclitaxel to treat this disease. This research was done because currently there is no effective treatment for urothelial cancer that has progressed after prior chemotherapy. Nab-paclitaxel is a formulation of the chemotherapeutic drug paclitaxel that is combined with a human protein called albumin. In Canada, nab-paclitaxel is currently approved for the treatment of metastatic breast cancer. This drug has been tested in other cancers and has shown promising activity in lung cancer, melanoma and pancreatic cancer. Information from research studies suggests that nab-paclitaxel may be a useful treatment for urothelial cancer.

For more information please visit the [CCTG BL12 trial page](https://www.ctg.queensu.ca).